June 17, 2025
Repurposing MDM2 Inhibitors for Lung Cancer
Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.
Nature
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
June 17, 2025
Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.
Nature
May 20, 2025
FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.
Oncology Nursing News
May 19, 2025
New AI model Sybil predicts future lung cancer risk from a single CT scan, offering hope for personalized screening, especially for Asian never-smokers.
American Thoracic Society
May 14, 2025
AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).
Fierce Pharma
May 5, 2025
A major Australian-Canadian lung cancer screening study found that 73% of high-risk participants had incidental findings during baseline CT scans, with 10% requiring clinical follow-up, highlighting significant inconsistencies in how these findings are reported to doctors and raising important questions about standardization as Australia prepares to launch its national screening program in 2025.
MJA
April 21, 2025
Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.
Oncology News Central
April 16, 2025
Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.
Nature
April 11, 2025
Chest CT scans used for lung cancer screening can do more than just find early lung cancer. These scans can also detect heart problems and early emphysema, offering a three-in-one health check for people at risk.
ScienceDirect
April 7, 2025
Oncologists have discovered that difficulties treating and managing the most common type of lung cancer, adenocarcinoma or non-small cell lung cancer, is related to a protein called agrin.
Roswell Park
April 3, 2025
A study of over 10,000 people showed that sticking with regular lung cancer screening leads to better detection of early-stage cancer. However, fewer people returned for follow-up screenings each year.
Pulmonology Advisor
April 1, 2025
Researchers at Johns Hopkins Medicine have developed an innovative computer model that could significantly improve immunotherapy outcomes for lung cancer patients.
John Hopkins Medicine
March 31, 2025
A new JAMA review shows that small cell lung cancer, which affects 95% smokers and has only 12-30% five-year survival, is seeing breakthrough improvements with immunotherapy extending survival to 56 months for early-stage disease, though advanced cases remain challenging with most patients relapsing within three months.
JAMA
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.